Artificial Blood
Artificial blood refers to medical products intended to replace natural human blood, designed for room-temperature storage, freedom from blood-type matching, and large-scale production. The main technological approaches include hemoglobin-based oxygen carriers, perfluorocarbon emulsions, and stem-cell-cultured red blood cells.
Timeline (last 90 days)
The US military's goal in developing artificial blood is not to completely replace real human blood, but to provide a bridging solution in emergencies, buying time for the evacuation of the wounded.
The US military has continuously invested in research and development in the field of artificial blood for many years, attempting to fundamentally change the game rules of battlefield emergency care.
The main current technical routes for artificial blood include hemoglobin-based oxygen carriers, perfluorocarbon emulsions, and stem-cell-cultured red blood cells.
If artificial blood technology matures and achieves mass production, it can alleviate the difficulties of blood transfusion in medical institutions in remote areas, at emergency sites and in mass casualty events, and avoid the risk of transmission of blood-borne infectious diseases.
The development of artificial blood has sparked ethical discussions, including who should get priority access to scarce resources, whether all wounded on the battlefield can receive it equally, and whether technological monopoly exacerbates global inequality in medical resources.
All Facts (5)
The US military's goal in developing artificial blood is not to completely replace real human blood, but to provide a bridging solution in emergencies, buying time for the evacuation of the wounded.
50%UnverifiedThe US military has continuously invested in research and development in the field of artificial blood for many years, attempting to fundamentally change the game rules of battlefield emergency care.
50%UnverifiedThe main current technical routes for artificial blood include hemoglobin-based oxygen carriers, perfluorocarbon emulsions, and stem-cell-cultured red blood cells.
50%UnverifiedThe development of artificial blood has sparked ethical discussions, including who should get priority access to scarce resources, whether all wounded on the battlefield can receive it equally, and whether technological monopoly exacerbates global inequality in medical resources.
50%UnverifiedIf artificial blood technology matures and achieves mass production, it can alleviate the difficulties of blood transfusion in medical institutions in remote areas, at emergency sites and in mass casualty events, and avoid the risk of transmission of blood-borne infectious diseases.
50%